Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells
Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells
复制标题
DOI：
10.2337/db14-0656
复制
发表时间：
2015-02-01
期刊：
影响因子：
7.7
通讯作者：
Le Blanc, Katarina
中科院分区：
文献类型：
--
作者：
Carlsson, Per-Ola;Schwarcz, Erik;Le Blanc, Katarina
在1型糖尿病中保持内源性胰岛素分泌是一个有吸引力的临床目标，这为长期恢复葡萄糖代谢提供了可能性。间充质基质细胞（MSC）构成，基于动物研究，一个有前途的干预策略的疾病。这项前瞻性临床研究描述了这种细胞干预策略对新近发病的1型糖尿病患者的转化。20例新诊断为1型糖尿病的成年患者入组并随机分配至MSC治疗组或对照组。在1年随访时，根据混合餐耐量试验（MMTT）的血液中C肽浓度分析残留β细胞功能。对照组患者在第1年期间C肽峰值和C肽（以曲线下面积计算）均出现损失，而MSC治疗组患者的这些反应得以保留甚至增加。重要的是，没有观察到MSC治疗的副作用。我们的结论是，自体MSC治疗新发1型糖尿病是一种安全和有前途的干预疾病进展和保护β细胞功能的策略。
The retention of endogenous insulin secretion in type 1 diabetes is an attractive clinical goal, which opens possibilities for long-term restoration of glucose metabolism. Mesenchymal stromal cells (MSCs) constitute, based on animal studies, a promising interventional strategy for the disease. This prospective clinical study describes the translation of this cellular intervention strategy to patients with recent-onset type 1 diabetes. Twenty adult patients with newly diagnosed type 1 diabetes were enrolled and randomized to MSC treatment or to the control group. Residual beta-cell function was analyzed as C-peptide concentrations in blood in response to a mixed-meal tolerance test (MMTT) at 1-year follow-up. In contrast to the patients in the control arm, who showed loss in both C-peptide peak values and C-peptide when calculated as area under the curve during the 1st year, these responses were preserved or even increased in the MSC-treated patients. Importantly, no side effects of MSC treatment were observed. We conclude that autologous MSC treatment in new-onset type 1 diabetes constitutes a safe and promising strategy to intervene in disease progression and preserve beta-cell function.